The purpose of this topic is to develop technologies to characterize glycan moieties of glycoproteins to enhance the diagnostic capability of protein-based biomarkers. The specific goals of the…
Ended Definitive Contract Awarded Last action
- Contract number
- HHSN261200900034C
- Awardee
-
Siamab Therapeutics, Inc. UEI DJM5GUE2NWD7
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $799,889
Award facts
- Opportunity
-
- NP Solicitation number
- Contract value 100% obligated
- $799,889.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541990 All Other Professional, Scientific, and Technical Services
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 1 offer Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Vista, CA 92081, USA
- Research
- SBIR Program Phase II Action
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Vendor DUNS or Name Change - Non-Novation | $0 | |
| Original award | $799,889 |
About this award
This is a Phase II Small Business Innovation Research (SBIR) contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Siamab Therapeutics, Inc. The purpose of the contract is to develop technologies to characterize glycan moieties of glycoproteins in order to enhance the diagnostic capability of protein-based biomarkers. The specific goals include expanding the number of features for an existing sialic acid glycan array, optimizing the serum assay protocol, evaluating methods for scale-up production, and collaborating with NCI's Early Detection Research Network to validate the glycan array clinically. The contract has a ceiling value of $799,889.00 and a completion date of September 29, 2012.
Description
The purpose of this topic is to develop technologies to characterize glycan moieties of glycoproteins to enhance the diagnostic capability of protein-based biomarkers. The specific goals of the phase II project are to: 1) expand the number of features above 54 for the existing V7 sialic acid glycan array and perform preliminary validation with small numbers of serum samples, 2) optimize the serum assay protocol for the larger sialic acid glycan array and assay specificity and sensitivity will be more thoroughly characterized, 3) evaluate methods for scale-up of production of the larger sialic acid glycan arrays, and 4) collaborate with investigators in NCI's early detection research network to validate clinically, and with statistical significance, the larger sialic acid glycan array developed in this project. The ultimate goal will be to identify and validate an actual "HIT" (particular antibody or pattern of antibodies that is predictive of cancer risk and/or prognosis), that can subsequently be commercialized.
Quick answers
Who was awarded contract HHSN261200900034C?
HHSN261200900034C was awarded to Siamab Therapeutics, Inc. by National Cancer Institute (National Institutes of Health) on September 30, 2009.
How much is contract HHSN261200900034C worth?
The government has obligated $799,889 on HHSN261200900034C.
Was contract HHSN261200900034C competed?
The extent of competition for HHSN261200900034C was full and open competition after exclusion of sources. The government received 1 offer. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award